



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : ZHI et al.
Serial No. : 10/589,920
Filed : August 17, 2006
Art Unit : 1614
Examiner : Unknown
Conf. No. : 3750
Cust. No. : 20985
Title : GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Dear Sir:

Transmitted herewith are an Information Disclosure Statement (3 pages), Forms PTO-1449 (3 pages), cited non U.S. patent references and a return postcard for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Dated: November 21, 2006

Attorney Docket No. 18202-027US1 / 1110US

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	ZHI et al.	Art Unit :	1614
Serial No. :	10/589,920	Examiner :	Unknown
Filed :	August 17, 2006	Conf. No. :	3750
		Cust. No. :	20985
Title :	GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Because this Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §1.97-1.98. Forms PTO-1449 (3 pages) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following pending U.S., International and National Phase Applications that have one or more common inventors and/or are commonly owned:

Applicant : ZHI et al.
Serial No. : 10/589,920
Filed : August 17, 2006

Attorney's Docket No.: 18202-027US1 /1110US
Information Disclosure Statement

<u>Docket No.</u>	<u>U.S.S.N.</u>	<u>Filed</u>	<u>Publ. No.</u>
002007/1002F	08/141,246	10/22/93	n/a
002009/1002H	08/141,496	10/22/93	n/a
002017/1002P	11/300,039	12/13/05	2006-0106072
004003/1026C	10/847,732	05/17/04	2004-0209839
005003/1028C	10/360,580	02/05/03	2004-0019072
013002/1062B	10/238,363	09/09/02	2003-0186970
013003/1062C	11/340,282	01/25/06	n/a
015003/1073C	11/165,769	06/23/05	2005-0288350
017002/1081B	11/344,690	01/31/06	2006-0128740
018001/1082	10/080,503	02/22/02	2002-0183314
020002/1088B	11/411,676	04/25/06	2006-0194827
022US1/1096US	10/564,578	01/13/06	n/a
028US1/1112US	10/590,119	08/18/06	n/a
030US1/1111US	10/566,569	01/31/06	n/a
033US2/1051BUS	11/448,365	06/06/06	n/a
035002/1059B	10/229,649	08/27/02	2003-0013766
048001/1087	10/684,212	10/11/03	2004-0152717
057002/1091B	11/445,844	06/02/06	2006-0223839
072P01/P1123	60/753,302	12/21/05	n/a

<u>Docket No.</u>	<u>Intl. No.</u>	<u>Filed</u>	<u>Publ. No.</u>
023WO1/1097PC	PCT/US04/023788	07/16/04	2005/009104
024WO1/1098PC	PCT/US04/023093	07/16/04	2005/016255
026WO1/1100PC	PCT/US04/023010	07/16/04	2005/010202
028WO1/1112PC	PCT/US05/07867	03/11/05	2005/090282
068WO1/1119PC	PCT/US06/23111	6/12/06	Awaiting
069WO1/1124PC	PCT/US06/26067	06/30/06	Awaiting


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant : ZHI et al.
Serial No. : 10/589,920
Filed : August 17, 2006

Attorney's Docket No.: 18202-027US1 /1110US
Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,




Stephanie Seidman
Reg. No. 33,779

Dated: November 21, 2006

Attorney Docket No. 18202-027US1 / 1110US
Address all correspondence to:
Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18202-027US1/1110US	Application No. 10/589,920
	Applicant ZHI et al.			
	Filing Date August 17, 2006		Group Art Unit 1614	



U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2003/0073703	04/17/03	Coghlan et al.	514	257	07/23/02
	AB	Re 28,819	05/18/76	Thompson	514	174	04/16/75
	AC	3,710,795	01/16/73	Higuchi et al.	424	424	09/29/70
	AD	4,044,126	08/23/77	Cook et al.	514	180	07/09/76
	AE	4,328,245	05/04/82	Yu et al.	514	530	02/13/81
	AF	4,358,603	11/09/82	Yu	560	2	04/16/81
	AG	4,364,923	12/21/82	Cook et al.	424	46	04/30/81
	AH	4,409,239	10/11/83	Yu	514	530	01/21/82
	AI	4,410,545	10/18/83	Yu et al.	514	530	05/10/82
	AJ	4,414,209	11/08/83	Cook et al.	514	180	06/13/77
	AK	4,522,811	06/11/85	Eppstein et al.	514	2	07/08/82
	AL	4,981,784	01/01/91	Evans et al.	435	6	11/30/88
	AM	5,033,252	07/23/91	Carter	53	425	07/30/90
	AN	5,052,558	10/01/91	Carter	206	439	07/27/90
	AO	5,071,773	12/10/91	Evans et al.	436	501	10/20/87
	AP	5,323,907	06/28/94	Kalvelage	206	531	03/15/93
	AQ	5,506,102	04/09/96	McDonnell	435	6	10/28/93
	AR	5,688,810	11/18/97	Jones et al.	514	311	06/05/95
	AS	5,693,646	12/02/97	Jones et al.	514	285	06/05/95
	AT	5,696,127	12/09/97	Jones et al.	514	285	06/05/95
	AU	5,696,133	12/09/97	Jones et al.	514	314	06/05/95
	AV	6,068,976	05/30/00	Briggs et al.	435	6	03/19/96
	AW	6,380,207	04/30/02	Coghlan et al.	514	285	02/13/98
	AX	6,506,766	01/14/03	Coghlan et al.	514	285	07/05/02
	AY	6,696,459	02/24/04	Jones et al.	514	285	10/14/97

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-027US1/1110US	Application No. 10/589,920
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant ZHI et al.	
		Filing Date August 17, 2006	Group Art Unit 1614

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AZ	03/037905	05/08/03	PCT				
	BA	02/02565	01/10/02	PCT				
	BB	99/041257	08/19/99	PCT				
	BC	99/041256	08/19/99	PCT				
	BD	95/031722	11/23/95	PCT				
	BE	96/029405	09/26/96	PCT				
	BF	96/019458	06/27/96	PCT				
	BG	1053239	01/08/03	EP				
	BH	1053240	04/16/03	EP				
	BI	1382597	01/21/04	EP				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BJ	Allegretto et al., "Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism," <i>Journal of Biological Chemistry</i> , 268(35):26625-26633, (1993). Erratum in: <i>Journal of Biological Chemistry</i> , 269(10):7834, (1994).
	BK	Ansel, H.C., <i>Introduction to Pharmaceutical Dosage Forms</i> , Fourth Edition, Lea and Febiger, Philadelphia, P.A., p. 126, (1985).
	BL	Bains and Tacke, "Silicon chemistry as a novel source of chemical diversity in drug design," <i>Current Opinion in Drug Discovery and Development</i> , 6(4):526-543, (2003).
	BM	Berger et al., "Interaction of glucocorticoid analogues with the human glucocorticoid receptor," <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 41:733-748, (1992).
	BN	Cheng and Prusoff, "Relationship between the inhibition constant (K _i) and the concentration of inhibitor which causes 50 per cent inhibition (I ₅₀) of an enzymatic reaction," <i>Biochemical Pharmacology</i> , 22:3099-3108, (1973).
	BO	Edwards et al., "Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines potent, orally active, nonsteroidal progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> , 41(15):2779-2785, (1998).
	BP	Evans et al., "The steroid and thyroid hormone receptor superfamily," <i>Science</i> , 240:889-895, (1988).
	BQ	Fingl et al., <i>The Pharmacological Basis of Therapeutics</i> , Ch. 1, Eds. Goodman and Gilman, Macmillan Publishing Co., New York, N.Y., pp. 1-46, (1975).
	BR	Nogady, T., <i>Medicinal Chemistry A Biochemical Approach</i> , Oxford University Press, New York, N.Y., pp. 388-392, (1985).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-027US1/1110US	Application No. 10/589,920
		Applicant ZHI et al.	
		Filing Date August 17, 2006	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BS	O'Reilly et al., "Cotransfection and recombinant virus identification" in <i>Baculovirus Expression Vectors</i> , Ch. 13, O'Reilly et al., Eds., W. H. Freeman, New York, N.Y., pp. 139-179, (1992).
	BT	Pathirana et al., "Nonsteroidal human progesterone receptor modulators from the marine alga <i>Cymopolia barbatam</i> ," <i>Molecular Pharmacology</i> , 47:630-635, (1995).
	BU	Pooley et al., "Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore," <i>Journal of Medicinal Chemistry</i> , 41:3461-3466, (1998).
	BV	Srinivasan and Thompson, "Overexpression of full-length human glucocorticoid receptor in <i>Spodoptera frugiperda</i> cells using the baculovirus expression vector system," <i>Molecular Endocrinology</i> , 4(2):209-216, (1990).
	BW	Tacke and Zilch, "Sila-substitution--a useful strategy for drug design?" <i>Endeavour</i> , 10:191-197, (1986).
	BX	Tegley et al., "5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> , 41(22):4354-4359, (1998).
	BY	Zhi et al., "5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines a novel class of nonsteroidal progesterone receptor modulators," <i>Bioorganic and Medicinal Chemistry Letters</i> , 8(23):3365-3370, (1998).
	BZ	Zhi et al., "5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists effect of A-ring modification," <i>Journal of Medicinal Chemistry</i> , 42(8):1466-1472, (1999).
	CA	Zhi et al., "5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines a novel class of nonsteroidal human progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> , 41(3):291-302, (1998).
	CB	Zhi et al., "5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators," <i>Journal of Medicinal Chemistry</i> , 46(19):4104-4112, (2003).
	CC	Zhi et al., "Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13(12):2075-2078, (2003).
	CD	Zhi et al., "Synthesis and biological activity of 5-methylidene1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13(12):2071-2074, (2003).
	CE	Zhi et al., "Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines," <i>Bioorganic and Medicinal Chemistry Letters</i> , 10:415-418, (2000).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	